Tecartus denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tecartus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Tecartus as Not Medically Necessary — and How to Appeal

Tecartus (brexucabtagene autoleucel) is an FDA-approved CAR-T cell therapy for relapsed or refractory mantle cell lymphoma (MCL) and adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). BCBS medical-necessity denials for Tecartus typically assert one or more of the following: the patient has not failed the required number or type of prior therapies; the patient's performance status or organ-function does not meet the criteria in BCBS's medical policy; the treating center is not on the REMS-approved authorized treatment center (ATC) list; or the clinical documentation submitted at the time of prior-authorization was insufficient.

## Why This Denial Is Appealable

BCBS's CAR-T medical policy is built around the FDA-approved indication and must track the label criteria. If the patient's diagnosis, prior-therapy history, and clinical status are documented fully, and they match the FDA-approved indication, the denial cannot be sustained. The most common underlying problem in medical-necessity denials is a documentation gap rather than a true clinical mismatch — the chart information was not submitted in a form that allows a reviewer to map each policy criterion to a specific chart fact. A well-organized, criterion-mapped appeal resolves most of these denials.

## Federal Appeal Framework

• Internal appeal: File within 180 days. BCBS must decide within 30 days (pre-service) or 60 days (post-service).
• Expedited appeal (72 hours): MCL and B-ALL are aggressive malignancies with time-sensitive treatment windows — document clinical urgency and request expedited review.
• Peer-to-peer review: Request immediately. BCBS must provide access to a physician reviewer with relevant specialty expertise. A hematologist-oncologist peer-to-peer is frequently decisive for CAR-T denials.
• External review (ACA §2719 / ERISA §503): If internal appeal fails, file for external review within the ~4-month window. External reviewers are independent board-certified hematologist-oncologists.

## Documentation to Gather

1. Pathology and molecular diagnosis: Biopsy with immunohistochemistry and molecular studies confirming MCL (including cyclin D1, t(11;14) by FISH/cytogenetics) or B-ALL (flow cytometry, cytogenetics, molecular markers) — obtain the exact pathology report, not just the clinical summary. 2. Complete prior-therapy history: For each prior treatment line: regimen name, start date, end date, best response achieved, and reason for discontinuation. The FDA-approved label and BCBS policy each specify prior-therapy requirements — confirm the patient's history meets them per the prescribing information. 3. Performance status and organ-function documentation: The most recent ECOG performance status documented in the chart; recent laboratory results and cardiac assessment (e.g., echocardiogram for LVEF) — check the FDA label for which organ-function parameters are part of the approved indication framework and ensure those are in the chart. 4. REMS and ATC confirmation: Letter from the treating center confirming FACT accreditation and REMS-authorization status. If the treating center is not REMS-certified, document coordination with an in-network certified ATC; if no in-network ATC exists, invoke the network-adequacy out-of-network exception. 5. Treating hematologist-oncologist's medical-necessity letter: Explaining diagnosis, prior-therapy history, why the patient meets the FDA-approved indication, and why Tecartus is the appropriate treatment at this juncture per the applicable NCCN guideline.

## Criteria-Mapping Structure

Obtain BCBS's CAR-T medical policy and the Tecartus FDA-approved prescribing information. List every criterion and map it to a specific chart document:

| Policy / Label Criterion | Chart Documentation | Document Location | |---|---|---| | Confirmed diagnosis (MCL or B-ALL) | Pathology report | Date + lab name | | Prior-therapy requirement met | Treatment history table | Chart dates | | Performance status within range | Most recent office note | Date of assessment | | Organ-function parameters met | Lab results + echo | Report dates | | FACT-accredited REMS-certified ATC | ATC credential letter | Treating center |

Submit the criteria-mapped package as the first document in the appeal package, with the supporting evidence tabbed and labeled to match each row.